Clinical Trial Update: Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial [Phase 3]

View source ↗

Summary

A Phase 3 trial in Japan evaluating pegylated interferon alfa-2b in combination with ribavirin for hepatitis C has completed and results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegylated Interferon Alfa-2b (pegylated interferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2015-08-03